0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Contribution |

Voltage-Gated Potassium Channel Autoimmunity Mimicking Creutzfeldt-Jakob Disease FREE

Michael D. Geschwind, MD, PhD; K. Meng Tan, MD; Vanda A. Lennon, MD, PhD; Ramon F. Barajas Jr, BS; Aissa Haman, MD; Christopher J. Klein, MD; S. Andrew Josephson, MD; Sean J. Pittock, MD
[+] Author Affiliations

Author Affiliations: Memory and Aging Center, Department of Neurology, University of California, San Francisco (Drs Geschwind, Haman, and Josephson and Mr Barajas); and Departments of Laboratory Medicine and Pathology (Drs Tan, Lennon, and Pittock), Neurology (Drs Lennon, Klein, and Pittock), and Immunology (Dr Lennon), Mayo Clinic College of Medicine, Rochester, Minnesota.


Arch Neurol. 2008;65(10):1341-1346. doi:10.1001/archneur.65.10.1341.
Text Size: A A A
Published online

Background  Rapidly progressive dementia has a variety of causes, including Creutzfeldt-Jakob disease (CJD) and neuronal voltage-gated potassium channel (VGKC) autoantibody–associated encephalopathy.

Objective  To describe patients thought initially to have CJD but found subsequently to have immunotherapy-responsive VGKC autoimmunity.

Design  Observational, prospective case series.

Setting  Department of Neurology, Mayo Clinic, and the Memory and Aging Center, University of California, San Francisco.

Patients  A clinical serologic cohort of 15 patients referred for paraneoplastic autoantibody evaluation. Seven patients were evaluated clinically by at least one of us. Clinical information for the remaining patients was obtained by physician interview or medical record review.

Main Outcome Measures  Clinical features, magnetic resonance imaging abnormalities, electroencephalographic patterns, cerebrospinal fluid analyses, and responses to immunomodulatory therapy.

Results  All the patients presented subacutely with neurologic manifestations, including rapidly progressive dementia, myoclonus, extrapyramidal dysfunction, visual hallucinations, psychiatric disturbance, and seizures; most (60%) satisfied World Health Organization diagnostic criteria for CJD. Magnetic resonance imaging abnormalities included cerebral cortical diffusion-weighted imaging hyperintensities. Electroencephalographic abnormalities included diffuse slowing, frontal intermittent rhythmic delta activity, and focal epileptogenic activity but not periodic sharp wave complexes. Cerebrospinal fluid 14-3-3 protein or neuron-specific enolase levels were elevated in 5 of 8 patients. Hyponatremia was common (60%). Neoplasia was confirmed histologically in 5 patients (33%) and was suspected in another 5. Most patients' conditions (92%) improved after immunomodulatory therapy.

Conclusions  Clinical, radiologic, electrophysiologic, and laboratory findings in VGKC autoantibody–associated encephalopathy may be confused with those of CJD. Serologic evaluation for markers of neurologic autoimmunity, including VGKC autoantibodies, may be warranted in suspected CJD cases.

Figures in this Article

Creutzfeldt-Jakob disease (CJD), a prion disease with no established disease-modifying treatment,1 is an important consideration in rapidly progressive dementia accompanied by myoclonus, parkinsonism, or ataxia.2 The diagnosis is supported by characteristic abnormalities on electroencephalography (EEG)3 or brain magnetic resonance imaging (MRI)4,5 and possibly by elevation of neuronal injury markers in cerebrospinal fluid (CSF).68 Creutzfeldt-Jakob disease is mimicked clinically by several other conditions, particularly rapid presentations of other neurodegenerative diseases and autoimmune neurologic conditions.8,9

Voltage-gated potassium channel (VGKC) autoantibodies were reported initially in acquired neuromyotonia10 and subsequently in Morvan syndrome,11 limbic encephalitis,12 other subacute encephalopathies,13 and limited manifestations of autoimmune dysautonomia.14 Conditions of most patients improve after early initiation of antibody-depleting immunomodulatory therapies.15 The observations described in this article, made independently at 2 separate institutions, involve 15 patients given an initial diagnosis of CJD but subsequently confirmed to have VGKC autoantibody–associated encephalopathy.

Between January 1, 2001, and December 31, 2007, the Mayo Clinic Neuroimmunology Laboratory's serologic evaluation and clinical interpretive service detected serum VGKC autoantibodies in 15 patients in whom CJD was suspected on initial clinical evaluation by a consultant neurologist from approximately 150 000 samples tested on a clinical service basis for autoantibody markers of autoimmune (possibly paraneoplastic) neurologic disease. These autoantibodies were detected incidentally during immunofluorescence screening16 and were confirmed by means of radioimmunoprecipitation assay using antigen solubilized cerebral cortical membranes complexed with 125I-labeled α-dendrotoxin.17

Four patients were referred for evaluation to the Department of Neurology, Mayo Clinic, and 3 to the Rapidly Progressive Dementia Program, Memory and Aging Center, University of California, San Francisco (UCSF). Eight patients were evaluated at other institutions. Clinical information was obtained by means of structured patient and family interviews, medical record review, or physician telephone interview. The Mayo Clinic and UCSF institutional review boards approved the study.

Seven of the 15 patients were women; the median patient age was 69 years. The median serum VGKC autoantibody level was 1.24 nmol/L (range, 0.16-51.9 nmol/L; reference range, ≤0.02 nmol/L). The clinical presentations, EEG and MRI findings, VGKC autoantibody titers, and treatment responses of the 7 patients evaluated directly by us are summarized in the Table.

Table Graphic Jump LocationTable. Clinical Characteristics of 7 VGKC Ab–Positive Patients With Suspected CJD, Evaluated Directly by the Authors
CLINICAL PRESENTATIONS

In all cases, neurologic symptoms were subacute in onset. The median time from neurologic symptom onset to serologic diagnosis was 5 months (range, 0-13 months); median follow-up from onset was 9 months (range, 1-88 months). All of the patients had short-term memory impairment, 12 had myoclonus, 12 had seizures, 10 had behavioral or affective disturbance, 8 had dyssomnia, 6 had extrapyramidal dysfunction, 5 had autonomic dysfunction, 5 had gait ataxia, and 5 had visual hallucinations. Nine patients (60%) satisfied the World Health Organization diagnostic criteria for sporadic CJD18: 3 probable and 6 possible. Nine patients had hyponatremia (presumed to reflect hypothalamic involvement), including 2 with hyperphagia.

Five patients had documented coexisting organ-specific autoimmune disease: 3 with thyroiditis (1 with vitiligo) and 2 with diabetes mellitus. Two patients had a remote history of neoplasia in remission. Active neoplasia was confirmed histologically in 3 patients (2 had colonic adenocarcinoma and 1 had renal oncocytoma) and was suspected in 5 others (1 had a prostatic nodule and a serum prostate-specific antigen level elevation and 4 had mass lesions on thoracic or abdominal computed tomography).

Comprehensive serologic evaluation19 documented coexisting organ-specific autoantibodies in 8 patients. Six patients had autoantibody markers of thyrogastric autoimmunity: 4 had striated muscle autoantibodies, 3 had glutamic acid decarboxylase (65-kDa isoform) autoantibodies, and 2 had thyroid peroxidase autoantibodies. Three patients had autoantibodies that frequently accompany cancer: Purkinje cell cytoplasmic autoantibody type 2,20 neuronal ganglionic acetylcholine receptor autoantibody,21 and N-type voltage-gated calcium channel autoantibody.22

INVESTIGATIONS

Brain MRI abnormalities, noted in 9 of 13 patients in whom images or reports were available, included cerebral cortical diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) abnormalities in 2 (Figure 1A-C and Figure 2), T2-weighted or FLAIR hyperintensities in 5 (all involving hippocampi and 2 involving additional cerebral foci), and generalized atrophy in 2. Both patients with apparent DWI abnormalities had normal attenuation diffusion coefficient maps.

Place holder to copy figure label and caption
Figure 1.

Brain magnetic resonance images of a patient with immunotherapy-responsive voltage-gated potassium channel (VGKC) autoimmunity and renal oncocytoma illustrate increased signal in the left anterior cingulate gyrus and insular cortex on diffusion-weighted imaging (A, arrows) and fluid-attenuated inversion recovery sequences (B and C, arrows). Indirect immunofluorescence testing of the patient's serum revealed IgG binding to VGKC-rich synapses in mouse cerebellar cortex (D). ML indicates molecular layer; GL, granular layer; and PC, Purkinje cells (unstained).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Diffusion-weighted magnetic resonance images in a patient with immunotherapy-responsive voltage-gated potassium channel autoimmunity illustrate increased signal in the left temporo-occipital cortex (A and C, arrows) and the bilateral mesial frontal cortex (B, arrows).

Graphic Jump Location

The CSF analysis in 10 patients revealed elevated protein levels in 3 (0.057-0.112 g/dL; range, 0.014-0.045 g/dL [to convert to grams per liter, multiply by 10.0]), lymphocytosis in 2 (white blood cell counts, 6 and 28/μL [to convert to ×109 per liter, multiply by 0.001]), and supernumerary (4) oligoclonal bands in 1. The CSF markers of neuronal injury were elevated in 5 of 8 patients tested: 14-3-3 protein (National Prion Disease Pathology Surveillance Unit, Cleveland, Ohio) was positive in 4 and neuron-specific enolase (Mayo Medical Laboratories, Rochester) was positive in 2.

The EEG findings were abnormal in 9 of 13 patients with available data. All 9 patients had diffuse slowing, 1 had frontal intermittent rhythmic delta activity, and 3 had focal epileptogenic activity (1 temporal, 1 frontal, and 1 frontotemporal). None had periodic sharp wave complexes.

TREATMENT

Information about initial treatment and outcome was available for 13 patients: 9 received corticosteroids, 2 received intravenous immunoglobulin, and 2 received plasmapheresis and corticosteroids combined. Clinical improvement was reported by the treating physician in 12 patients (92%; 5 dramatic, 6 moderate, and 1 mild). Of those 12 patients, 8 experienced relapses that required continued or repeated immunomodulatory therapy: corticosteroids (7 patients), immunoglobulin (2 patients), plasmapheresis (1 patient), mycophenolate mofetil (2 patients), rituximab (1 patient), or azathioprine (1 patient).

ILLUSTRATIVE PATIENT 1

A 73-year-old woman (patient 1 in the Table) presented to the UCSF Memory and Aging Center with an 8-month history of involuntary movements of the right upper extremity and face and a 4-month history of rapidly progressive cognitive decline, abulia, insomnia, and frequent falls. Examination revealed fluctuating alertness, a Folstein Mini-Mental State Examination score of 18 (maximum possible score is 30) (impairment across multiple domains), myoclonus and spasms of the right upper extremity and face, mild generalized bradykinesia, right upper extremity rigidity, and gait ataxia.

Laboratory evaluation revealed hyponatremia (sodium, 127 mEq/L [to convert to millimoles per liter, multiply by 1.0]) and 4 CSF-unique oligoclonal bands. The CSF 14-3-3 protein level was mildly elevated initially (considered “ambiguous” for CJD) but was normal on 2 subsequent spinal taps. Brain MRIs were considered suggestive of CJD, showing increased DWI and FLAIR signal in the left anterior cingulate gyrus and insula (Figure 1A-C); however, the attenuation diffusion coefficient map was normal. Biopsy of the left frontal lobe revealed microgliomatosis and neuronophagia without inflammation and astrocytic gliosis without vacuolation or prion deposition. During serologic evaluation for paraneoplastic autoantibodies, indirect immunofluorescence screening suggested the presence of VGKC specific IgG (Figure 1D). Reflex radioimmunoprecipitation assay confirmed the presence of VGKC autoantibodies (51.9 nmol/L; reference range, ≤0.02 nmol/L). N-type voltage-gated calcium channel autoantibody was also detected (0.17 nmol/L; reference range, ≤0.03 nmol/L). Computed tomography revealed a renal mass suggestive of adenoma.

After 3 days of intravenous methylprednisolone therapy, alertness, verbal output, and cognitive performance (a Mini-Mental State Examination score of 30) improved remarkably. Subsequent brain MRI showed reduced DWI and FLAIR hyperintensity in the left insula and cingulate gyri but new T2 hyperintensity involving the left caudate and putamen (data not shown). Repeated pulsed corticosteroid therapy was required in the ensuing 18 months for recurrent generalized tonic-clonic seizures and cognitive impairment; intravenous immunoglobulin therapy, plasmapheresis, mycophenolate therapy, and partial nephrectomy (confirming a renal oncocytoma) did not seem to provide additional benefit. Rituximab therapy commenced 23 months after onset was followed by considerable clinical improvement, comparable with that seen previously with pulsed corticosteroid therapy.

ILLUSTRATIVE PATIENT 2

A 75-year-old man (patient 4 in the Table) with a 50–pack-year history of smoking and a past diagnosis of colonic adenoma presented to Mayo Clinic with a 5-month history of cognitive impairment and a 3-month history of startle myoclonus, hypnagogic jerks, urinary and fecal incontinence, shuffling gait, and a presumed rapid eye movement sleep behavior disorder characterized by episodic screaming and thrashing. He scored 30 (maximum possible score is 38) on the Kokmen short test of mental status; short-term recall and abstract thinking were most impaired. Myoclonic jerks of both upper extremities and the face were observed, with hypomimia, hypophonia, and parkinsonian gait.

Brain MRI showed mild global atrophy. The CSF protein level was mildly elevated (0.057 g/dL; reference range, 0.014-0.045 g/dL), without lymphocytosis or oligoclonal bands. The EEG documented diffuse slowing during wakefulness and focal rhythmic theta activity (consistent with a frontal lobe seizure) during a typical sleep episode of abrupt yelling, right arm jerking, and stiffening. Movement laboratory evaluation documented spontaneous multifocal cortical myoclonus, and serologic evaluation revealed VGKC autoantibody (0.16 nmol/L) and striated muscle autoantibody (1:30 720; reference range, <1:60). Chest computed tomography revealed mediastinal lymphadenopathy; subsequent biopsy revealed hyalinized granulomata but no neoplasm.

Treatment with intravenous methylprednisolone led to complete resolution of all deficits (including a Kokmen score of 38), but pulsed corticosteroid treatment was required intermittently for 12 months because of neurologic relapse. In the following 18 months, he remained in remission without further treatment.

This article illustrates clinical presentations of VGKC autoimmunity that mimic CJD and demonstrates the potential for misdiagnosis of a reversible condition for a terminal one. This cohort's age and sex distribution23 and observed clinical manifestations18 (except for dysautonomia and hyponatremia) are compatible with CJD. Most patients fulfilled the World Health Organization diagnostic criteria, presenting with rapidly progressive dementia with myoclonus, extrapyramidal or cerebellar signs, visual disturbances, or psychiatric dysfunction.

Hyponatremia (60%) provides an important diagnostic clue favoring an autoimmune basis for neurologic disease.24 The frequency of neoplasia observed in these patients is consistent with our recent report of neoplasia in 33% of serologically ascertained cases of VGKC autoimmunity.16 The generally favorable response to immunomodulatory therapies accords with previous studies24,25 of treatment-responsive limbic encephalitis.

The VGKC autoimmunity is frequently associated with epileptic seizures16 and was a common finding in this cohort (80%). Although less commonly encountered, seizures are also a recognized and sometimes presenting feature of CJD.2628 Therefore, in an individual patient, the presence of seizures should prompt consideration of alternative diagnoses but should not exclude the possibility of CJD.

Two patients had DWI hyperintensities of the cerebral cortex on MRI, with both neuroradiologists reporting the appearance to be consistent with CJD.4 However, the absence of restricted diffusion on attenuation diffusion coefficient mapping in both patients is atypical for CJD. Because attenuation diffusion coefficient mapping is not performed at many imaging centers, these findings caution against overinterpreting the DWI series in isolation. The T2-weighted and FLAIR hyperintensities of the mesial temporal regions in 5 patients match recognized MRI appearances of autoimmune limbic encephalitis24,25 but are also compatible with CJD. For example, of 49 patients with sporadic CJD whose MRIs were performed at the UCSF, 94% had FLAIR or DWI hyperintensities of the limbic cortex, including the medial temporal lobes.29

Elevation of CSF neuronal injury markers, especially 14-3-3 protein (part of the World Health Organization diagnostic criteria)18 casts further doubt on the utility of these tests in the diagnosis of CJD.7 Diffuse slowing and other observed EEG abnormalities are recognized accompaniments of sporadic and variant CJD, although no patient had the periodic sharp wave complexes considered characteristic of sporadic CJD.30

The high VGKC autoantibody levels (>1.0 nmol/L in most patients), the reported improvement after immunomodulatory therapy, and the absence of VGKC autoantibodies in 10 UCSF patients with histologically confirmed CJD (9 sporadic and 1 familial) (M.D.G., unpublished data, 2008) suggest that these autoantibodies are true markers of neurologic autoimmunity and not an epiphenomenon of nonimmune-mediated neuronal degeneration.

The prevalence of VGKC autoimmunity in patients with suspected CJD requires further study. The experiences presented in this article, and the starkly divergent long-term outcomes for CJD and VGKC autoimmunity, justify comprehensive serologic evaluation for markers of autoimmune encephalopathy in patients with suspected CJD. Seropositivity for VGKC autoantibodies justifies early consideration of immunomodulatory therapy and thorough investigation for a neoplasm.

Correspondence: Sean J. Pittock, MD, Neuroimmunology Laboratory, Hilton 3-78F, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (pittock.sean@mayo.edu).

Accepted for Publication: April 29, 2008.

Author Contributions: Drs Geschwind and Tan and Mr Barajas and Dr Klein contributed equally to the article. Dr Tan had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Geschwind, Tan, Barajas, Klein, and Pittock. Acquisition of data: Geschwind, Tan, Barajas, Haman, Klein, and Josephson. Analysis and interpretation of data: Tan, Lennon, Barajas, and Pittock. Drafting of the manuscript: Tan, Barajas, Haman, Josephson, and Pittock. Critical revision of the manuscript for important intellectual content: Geschwind, Lennon, Barajas, Klein, and Pittock. Statistical analysis: Tan. Obtained funding: Geschwind and Pittock.Administrative, technical, and material support: Tan, Lennon, Barajas, Haman, and Klein. Study supervision: Geschwind, Lennon, and Pittock.

Financial Disclosure: None reported.

Additional Contributions: Norbert Campeau, MD, assisted with radiologic interpretation and image preparation; Stephen DeArmond, MD, PhD, provided neuropathologic evaluation; and Nicholas Barbaro, MD, provided neurosurgical assistance.

Korth  CPeters  PJ Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006;63 (4) 497- 501
PubMed Link to Article
Brown  PCathala  FCastaigne  PGajdusek  DC Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol 1986;20 (5) 597- 602
PubMed Link to Article
Levy  SRChiappa  KHBurke  CJYoung  RR Early evolution and incidence of electroencephalographic abnormalities in Creutzfeldt-Jakob disease. J Clin Neurophysiol 1986;3 (1) 1- 21
PubMed Link to Article
Young  GSGeschwind  MDFischbein  NJ  et al.  Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005;26 (6) 1551- 1562
PubMed
Shiga  YMiyazawa  KSato  S  et al.  Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 2004;63 (3) 443- 449
PubMed Link to Article
Sanchez-Juan  PGreen  ALadogana  A  et al.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006;67 (4) 637- 643
PubMed Link to Article
Chapman  T McKeel  DW  JrMorris  JC Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55 (9) 1396- 1397
PubMed Link to Article
Geschwind  MDHaman  AMiller  BL Rapidly progressive dementia. Neurol Clin 2007;25 (3) 783- 807, vii
PubMed Link to Article
Poser  SMollenhauer  BKraubeta  A  et al.  How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999;122 (pt 12) 2345- 2351
PubMed Link to Article
Hart  IKWaters  CVincent  A  et al.  Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997;41 (2) 238- 246
PubMed Link to Article
Barber  PAAnderson  NEVincent  A Morvan's syndrome associated with voltage-gated K+ channel antibodies. Neurology 2000;54 (3) 771- 772
PubMed Link to Article
Buckley  COger  JClover  L  et al.  Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50 (1) 73- 78
PubMed Link to Article
McKeon  AMarnane  MO'Connell  MStack  JPKelly  PJLynch  T Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. Arch Neurol 2007;64 (10) 1528- 1530
PubMed Link to Article
Viallard  JFVincent  AMoreau  JFParrens  MPellegrin  JLEllie  E Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005;53 (2) 60- 63
PubMed Link to Article
Hayat  GRKulkantrakorn  KCampbell  WWGiuliani  MJ Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. J Neurol Sci 2000;181 (1-2) 38- 43
PubMed Link to Article
Tan  KMLennon  VAKlein  CJBoeve  BFPittock  SJ Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70 (20) 1883- 1890
PubMed Link to Article
Vernino  SLennon  VA Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve 2002;26 (5) 702- 707
PubMed Link to Article
World Health Organization, Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation. Emerging and Other Communicable Diseases, Surveillance and Control. Geneva, Switzerland World Health Organization1998;1- 26
Pittock  SJYoshikawa  HAhlskog  JE  et al.  Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006;81 (9) 1207- 1214
PubMed Link to Article
Vernino  SLennon  VA New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000;47 (3) 297- 305
PubMed Link to Article
McKeon  ALennon  VAFealey  RDPittock  SJ The ganglionic acetylcholine receptor antibody (α3-AChR Ab): oncological, neurological and autoantibody accompaniments [abstract]. Ann Neurol 2007;62 ((suppl 11)) S72
Lennon  VAKryzer  TJGriesmann  GE  et al.  Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332 (22) 1467- 1474
PubMed Link to Article
Cousens  SNZeidler  MEsmonde  TF  et al.  Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. BMJ 1997;315 (7105) 389- 395
PubMed Link to Article
Vincent  ABuckley  CSchott  JM  et al.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127 (pt 3) 701- 712
PubMed Link to Article
Thieben  MJLennon  VABoeve  BFAksamit  AJKeegan  MVernino  S Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62 (7) 1177- 1182
PubMed Link to Article
Arruda  WOBordignon  KCMilano  JBRamina  R Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings [in Portuguese]. Arq Neuropsiquiatr 2004;62 (2A) 347- 352
PubMed Link to Article
Sanchez-Valle  RNos  CYagüe  JGraus  FDominguez  ASaiz  A Clinical and genetic features of human prion diseases in Catalonia: 1993-2002. Eur J Neurol 2004;11 (10) 649- 655
PubMed Link to Article
Yamanouchi  HBudka  HVass  K  Sr Unilateral Creutzfeldt-Jakob disease. Neurology 1986;36 (11) 1517- 1520
PubMed Link to Article
Vitali  PMaccagnano  EHaman  A  et al.  Improving MRI criteria for Jakob-Creutzfeldt disease (CJD) by the pattern of gray matter involvement on FLAIR and DWI MRI #IN2-2.005. Neurology 2008;70 ((suppl 1)) A8
Wieser  HGSchindler  KZumsteg  D EEG in Creutzfeldt-Jakob disease. Clin Neurophysiol 2006;117 (5) 935- 951
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Brain magnetic resonance images of a patient with immunotherapy-responsive voltage-gated potassium channel (VGKC) autoimmunity and renal oncocytoma illustrate increased signal in the left anterior cingulate gyrus and insular cortex on diffusion-weighted imaging (A, arrows) and fluid-attenuated inversion recovery sequences (B and C, arrows). Indirect immunofluorescence testing of the patient's serum revealed IgG binding to VGKC-rich synapses in mouse cerebellar cortex (D). ML indicates molecular layer; GL, granular layer; and PC, Purkinje cells (unstained).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Diffusion-weighted magnetic resonance images in a patient with immunotherapy-responsive voltage-gated potassium channel autoimmunity illustrate increased signal in the left temporo-occipital cortex (A and C, arrows) and the bilateral mesial frontal cortex (B, arrows).

Graphic Jump Location

Tables

Table Graphic Jump LocationTable. Clinical Characteristics of 7 VGKC Ab–Positive Patients With Suspected CJD, Evaluated Directly by the Authors

References

Korth  CPeters  PJ Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006;63 (4) 497- 501
PubMed Link to Article
Brown  PCathala  FCastaigne  PGajdusek  DC Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol 1986;20 (5) 597- 602
PubMed Link to Article
Levy  SRChiappa  KHBurke  CJYoung  RR Early evolution and incidence of electroencephalographic abnormalities in Creutzfeldt-Jakob disease. J Clin Neurophysiol 1986;3 (1) 1- 21
PubMed Link to Article
Young  GSGeschwind  MDFischbein  NJ  et al.  Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005;26 (6) 1551- 1562
PubMed
Shiga  YMiyazawa  KSato  S  et al.  Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 2004;63 (3) 443- 449
PubMed Link to Article
Sanchez-Juan  PGreen  ALadogana  A  et al.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006;67 (4) 637- 643
PubMed Link to Article
Chapman  T McKeel  DW  JrMorris  JC Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55 (9) 1396- 1397
PubMed Link to Article
Geschwind  MDHaman  AMiller  BL Rapidly progressive dementia. Neurol Clin 2007;25 (3) 783- 807, vii
PubMed Link to Article
Poser  SMollenhauer  BKraubeta  A  et al.  How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999;122 (pt 12) 2345- 2351
PubMed Link to Article
Hart  IKWaters  CVincent  A  et al.  Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997;41 (2) 238- 246
PubMed Link to Article
Barber  PAAnderson  NEVincent  A Morvan's syndrome associated with voltage-gated K+ channel antibodies. Neurology 2000;54 (3) 771- 772
PubMed Link to Article
Buckley  COger  JClover  L  et al.  Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50 (1) 73- 78
PubMed Link to Article
McKeon  AMarnane  MO'Connell  MStack  JPKelly  PJLynch  T Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. Arch Neurol 2007;64 (10) 1528- 1530
PubMed Link to Article
Viallard  JFVincent  AMoreau  JFParrens  MPellegrin  JLEllie  E Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005;53 (2) 60- 63
PubMed Link to Article
Hayat  GRKulkantrakorn  KCampbell  WWGiuliani  MJ Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. J Neurol Sci 2000;181 (1-2) 38- 43
PubMed Link to Article
Tan  KMLennon  VAKlein  CJBoeve  BFPittock  SJ Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70 (20) 1883- 1890
PubMed Link to Article
Vernino  SLennon  VA Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve 2002;26 (5) 702- 707
PubMed Link to Article
World Health Organization, Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation. Emerging and Other Communicable Diseases, Surveillance and Control. Geneva, Switzerland World Health Organization1998;1- 26
Pittock  SJYoshikawa  HAhlskog  JE  et al.  Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006;81 (9) 1207- 1214
PubMed Link to Article
Vernino  SLennon  VA New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000;47 (3) 297- 305
PubMed Link to Article
McKeon  ALennon  VAFealey  RDPittock  SJ The ganglionic acetylcholine receptor antibody (α3-AChR Ab): oncological, neurological and autoantibody accompaniments [abstract]. Ann Neurol 2007;62 ((suppl 11)) S72
Lennon  VAKryzer  TJGriesmann  GE  et al.  Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332 (22) 1467- 1474
PubMed Link to Article
Cousens  SNZeidler  MEsmonde  TF  et al.  Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. BMJ 1997;315 (7105) 389- 395
PubMed Link to Article
Vincent  ABuckley  CSchott  JM  et al.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127 (pt 3) 701- 712
PubMed Link to Article
Thieben  MJLennon  VABoeve  BFAksamit  AJKeegan  MVernino  S Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62 (7) 1177- 1182
PubMed Link to Article
Arruda  WOBordignon  KCMilano  JBRamina  R Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings [in Portuguese]. Arq Neuropsiquiatr 2004;62 (2A) 347- 352
PubMed Link to Article
Sanchez-Valle  RNos  CYagüe  JGraus  FDominguez  ASaiz  A Clinical and genetic features of human prion diseases in Catalonia: 1993-2002. Eur J Neurol 2004;11 (10) 649- 655
PubMed Link to Article
Yamanouchi  HBudka  HVass  K  Sr Unilateral Creutzfeldt-Jakob disease. Neurology 1986;36 (11) 1517- 1520
PubMed Link to Article
Vitali  PMaccagnano  EHaman  A  et al.  Improving MRI criteria for Jakob-Creutzfeldt disease (CJD) by the pattern of gray matter involvement on FLAIR and DWI MRI #IN2-2.005. Neurology 2008;70 ((suppl 1)) A8
Wieser  HGSchindler  KZumsteg  D EEG in Creutzfeldt-Jakob disease. Clin Neurophysiol 2006;117 (5) 935- 951
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 71

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles